39
Participants
Start Date
June 1, 2023
Primary Completion Date
June 1, 2025
Study Completion Date
June 1, 2026
Surufatinib,Serplulimab,Etoposide,Carboplatin
"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
Fujian Cancer Hospital, Fuzhou
Hunan Cancer Hospital
OTHER
Wuhan TongJi Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV